Liver disease has emerged as a critical and escalating public health concern worldwide, with the Asia-Pacific region at the forefront of this challenge due to its vast population and diverse socioeconomic landscape. Over the coming five decades, this region will experience profound changes in liver disease patterns, shaped by rapid urbanization, lifestyle modifications, advancements in medical technologies, and evolving public health strategies. This article offers an in-depth analysis of six transformative areas defining the trajectory of liver disease in the region. First, it highlights the alarming rise of metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatohepatitis, diseases driven by modern lifestyle factors and inherent metabolic susceptibilities. Concurrently, it celebrates the declining burden of viral hepatitis, underscoring the success of sustained public health interventions. However, new challenges are emerging, such as the growing impact of environmental and occupational exposures on liver health. Breakthroughs in genomic and epigenetic research promise to advance precision medicine, offering targeted therapeutic solutions. Additionally, the integration of artificial intelligence, big data, and telemedicine is poised to revolutionize liver disease management, improving accessibility and personalized care. Finally, the article emphasizes the critical role of robust health policies, preventive strategies, and cross-border collaboration in shaping a healthier future. By synthesizing these insights, the study aims to guide innovative and effective responses to the evolving liver disease landscape in the Asia-Pacific region.
Citations
Citations to this article as recorded by
Digital divide and healthcare service utilization among older adults with chronic liver disease in China: a nationwide cross-sectional study Yang Feng, Ke Pu, Chang Liu Scientific Reports.2026;[Epub] CrossRef
Association Between Sarcopenic Obesity–Related Scores and Liver Fibrosis in Patients with Steatotic Liver Disease: A Cross-Sectional Study Tatsuki Ichikawa, Satoshi Miuma, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Naohiro Komatsu, Mayuko Kakizoe, Ryusei Tanaka, Hisamitsu Miyaaki Diagnostics.2026; 16(2): 324. CrossRef
The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases Yirui Hu, Ye Yang, Shuyan Wang, Huikuan Chu npj Biofilms and Microbiomes.2026;[Epub] CrossRef
Liver Transplantation Following Immune Checkpoint Inhibitor Therapy: What Do We Need to Know from Clinical and Immunological Perspective? Hee Sun Cho, Soon Kyu Lee International Journal of Molecular Sciences.2026; 27(6): 2680. CrossRef
Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Heechul Nam, Sung Won Lee Alimentary Pharmacology & Therapeutics.2026; 63(10): 1427. CrossRef
Targeting the AMPK/ACC pathway with luteolin suppresses de novo lipogenesis and limits tumor burden in a MASH-HCC mouse model Gaoxuan Shao, Chenceng Sun, Chenhao Ye, Ying Liu, Jiashu Pan, Yujing Liu, Lu Lu, Lei Wang, Zemin Lin, Fan Yang, Guang Ji, Hanchen Xu Life Sciences.2026; 397: 124440. CrossRef
Global trends in metabolic-associated hepatocellular carcinoma: genetic and socio-demographic drivers Na Wu, Xinying Xiong, Xinyue Wang, Shuang Wei, Xinyu Shi, Yilin Chen, Wenjun Zhou, Jianying Wang, Lei Zhang, Baocheng Liu, Hualing Song, Huiting Yu, Guang Ji Hepatology International.2026;[Epub] CrossRef
Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim Clinical and Translational Gastroenterology.2026; 17(7): e01042. CrossRef
Antiviral Therapy and Post‐Resection Outcomes in Patients With Hepatitis B Virus‐Related Hepatocellular Carcinoma Jaehong Jeong, Jung Pyo Hong, Dong Yun Kim, Jae Seung Lee, Mi Na Kim, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Hye Won Lee Alimentary Pharmacology & Therapeutics.2026;[Epub] CrossRef
Trends and future projections of liver cancer attributable to metabolic dysfunction-associated steatohepatitis in China from 1990 to 2050 Jincheng Tang, Renyi Yang, Kexiong Li, Wei Peng, Zuomei He, Wenhui Gao, Puhua Zeng Scientific Reports.2025;[Epub] CrossRef
Bridging the Gap in Elimination of Hepatitis C Virus among People Who Use Drugs in South Korea Beom Kyung Kim Gut and Liver.2025; 19(5): 635. CrossRef
Precision prevention of liver cancer based on risk factors Jian-Guo Chen Exploration of Digestive Diseases.2025;[Epub] CrossRef
MAFLD in Vietnam: a neglected public health challenge requiring urgent policy action Thong Duy Vo, Huong Tu Lam Frontiers in Clinical Diabetes and Healthcare.2025;[Epub] CrossRef
First
Prev
